Clinical Trial Update: Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating an Ibrutinib-based combination therapy for newly diagnosed primary central nervous system lymphoma in transplant-ineligible patien…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: Canadian Cancer Trials Group | Conditions: Non-hodgkin Lymphoma | Phase 2 | Status: RECRUITING